NCT07169617View on ClinicalTrials.gov

Testing the SurVaxM Vaccine for Lung Cancer Prevention

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 25, 2026

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Lung Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Montanide ISA 51 VG

Given SC

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Sargramostim

Given SC

BIOLOGICAL

SVN53-67/M57-KLH Peptide Vaccine

Given SC

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

37920

University of Tennessee - Knoxville, Knoxville

60611

Northwestern University, Chicago

80045

Rocky Mountain Regional VA Medical Center, Aurora

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH